Mastek has announced the merger of Majesco with Cover-All (COVR), an NYSE listed core insurance systems and services provider. As part of the share swap deal, Majesco will be listed in the US while Cover-All shareholders' (includes potential dilution) would hold 16.5% of outstanding shares of the combined entity.

''We believe the deal valuations could be construed as base value for Mastek's insurance business even as incremental value could accrue, over time, with scale and synergy benefits. Assuming Mcap/sales deal multiple - itself at a 64% discount to comps - yields Rs 7.23 billion value for the insurance piece, in-line with our Rs 750 crore estimate, attributed in the Sept. 18, 2014 note,'' said ICICIdirect.

''We believe the insurance business post Agile acquisition and Cover-All merger could be a formidable player in the mid-market segment. Further, value creation in the insurance business is getting real with Majesco's US listing,'' it said.

''We believe the combined insurance business could be valued at 2.5x on Mcap/pro-forma sales metric (25% hold-co discount, 1.5-2x earlier) given deeper market expertise and cross-selling opportunities within the acquired clients while the services business could be valued at 3.5x trailing pro-forma EV/EBITDA. This translates to a fair value of Rs 600,'' it opined.

ICICIdirect has recommended 'Buy' on Mastek with target price of Rs 600 as against current market price (CMP) of Rs 410 in its report.

Disclaimer: IRIS has taken due care and caution in compilation of data for its web site. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.